Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To test the hypothesis that first-line treatment with atomoxetine provides superior efficacy than placebo for up to 12 weeks in improving the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). RESEARCH DESIGN AND METHODS: This double-blind, randomized, placebo-controlled, parallel clinical trial included 151 treatment-naïve children (n = 113) and adolescents (n = 38) with newly diagnosed (< or =3 months) ADHD. Atomoxetine dose was uptitrated from 0.5 to 1.2 mg/kg/day after two weeks. Outcome assessments included the ADHD Rating Scale-IV-Parent-reported Investigator-rated (ADHDRS-IV-Parent:Inv), the Clinical Global Impression of Severity of ADHD (CGI-ADHD-S), and the incidence of adverse events. Mixed-model repeated measures analysis was used to compare scale score changes between groups. CLINICAL TRIAL REGISTRATION: Trial registered at www.clinicaltrials.gov (study internal code: B4Z-XM-LYDM, identifier: NCT00191945). RESULTS: Most patients were male (79.2%), of caucasian origin (96.0%) and severely ill (72.5%). Their mean age was 10.3 years. Atomoxetine-treated patients showed greater reductions from baseline to week 12 of total ADHDRS-IV-Parent:Inv score than placebo-treated patients (least square mean difference: -7.9 [95% CI: -11.0 to -4.8], corresponding to a large effect size of 0.8). Between-group mean differences increased progressively with treatment exposure from week 6 to 12 (-2.7 [-4.9 to -0.6] for total and -1.6 [-2.9 to -0.3] for inattention scores). At the end of the study, 50% of atomoxetine-treated patients (14% with placebo) showed a reduction > or =40% in total ADHDRS-IV-Parent:Inv score, and only 29% (46% with placebo) were severely ill (by CGI-ADHD-S). Treatment-related adverse events were significantly more frequent with atomoxetine (65.0%) than with placebo (37.3%), the most frequent being decreased appetite and somnolence. Only one case of decreased appetite was rated as severe. No patient discontinued treatment because of adverse events. CONCLUSIONS: A continued improvement of symptoms is expectable until 12 weeks in treatment-naïve ADHD patients treated with atomoxetine as first-line medication. Chief limitations are the small, national sample size and the absence of data beyond the 12-week time-point.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Rosnow, R. L., & Rosenthal, R. (1996) · Psychological Methods · doi:10.1037/1082-989x.1.4.331 · Cited by 761
Solanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
Cited by
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R.-J., Escobar, R., Schacht, A., Pamulapati, S., Buitelaar, J. K., & Hoekstra, P. J. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.04.011 · Cited by 171
Self-citationSchwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Imaging the ADHD brain: disorder-specificity, medication effects and clinical translation
Rubia, K., Alegria, A., & Brinson, H. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.907526 · Cited by 146
“Interestingly, while brain function effects were relatively comparable for both drugs for inhibition and timing, only methylphenidate improved task performance [84,117,119], in line with the relatively slow behavioral effects of atomoxetine that typically are only observable after many weeks of treatment [141].”
BackgroundCubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M. J., Simmons, A., & Rubia, K. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhs296 · Cited by 116
Reed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
“8, after 12 weeks of atomoxetine treatment [131].”
BackgroundInfluentialCubillo, A., Smith, A. B., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2014) · Psychological Medicine · doi:10.1017/s0033291713000676 · Cited by 88
Stuhec, M., Munda, B., Svab, V., & Locatelli, I. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.006 · Cited by 83
Kowalczyk, O. S., Cubillo, A. I., Smith, A., Barrett, N., Giampietro, V., Brammer, M., Simmons, A., & Rubia, K. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.07.139 · Cited by 63
Smith, A., Cubillo, A., Barrett, N., Giampietro, V., Simmons, A., Brammer, M., & Rubia, K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.030 · Cited by 53
Chou, T.-L., Chia, S., Shang, C.-Y., & Gau, S. S.-F. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.024 · Cited by 44
Roskell, N. S., Setyawan, J., Zimovetz, E. A., & Hodgkins, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.904772 · Cited by 42
“No withdrawals due to adverse events were observed in either arm of the Montoya et al.54 trial.”
BackgroundJoseph, A., Ayyagari, R., Xie, M., Cai, S., Xie, J., Huss, M., & Sikirica, V. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-0962-6 · Cited by 38
“Trials: Biederman [28]; Biederman [29]; Block [32]; Coghill [33]; Dittmann [34]; Dittmann [35]; Findling [36]; Findling [37]; Garg [38]; Gau [40]; Hervas [41]; Ialongo [27]; Kelsey [42]; Kollins [43]; López [44]; Martenyi [45]; Montoya [48]; Newcorn [49]; Newcorn [50]; Palumbo [51]; Sallee [30]; Shang [52]; Spencer [3…”
BackgroundIsfandnia, F., El Masri, S., Radua, J., & Rubia, K. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105703 · Cited by 36
Fridman, M., Hodgkins, P. S., Kahle, J. S., & Erder, M. H. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.001 · Cited by 16
Metadata
- Authors
- Montoya, A., Hervas, A., Cardo, E., Artigas, J., Mardomingo, M. J., Alda, J. A., Gastaminza, X., García-Polavieja, M. J., Gilaberte, I., & Escobar, R.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2009-09-28
- Volume
- 25
- Issue
- 11
- Pages
- 2745-2754
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2157382328
- Cited by
- 64
- References
- 24
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.